| Source: |
| Type: |
| RIP3 Receptor‐Interacting Protein Kinase 3 Several cancers have decreased RIP3 expression and is associated with poorer prognosis, more aggressive tumor behavior, and resistance to chemotherapies. Restoration of RIP3 may promote necroptosis, providing a potential mechanism to overcome therapy resistance. |
| 1536- | Api, | Apigenin causes necroptosis by inducing ROS accumulation, mitochondrial dysfunction, and ATP depletion in malignant mesothelioma cells |
| - | in-vitro, | MM, | MSTO-211H | - | in-vitro, | MM, | H2452 |
| 1563- | Api, | MET, | Metformin-induced ROS upregulation as amplified by apigenin causes profound anticancer activity while sparing normal cells |
| - | in-vitro, | Nor, | HDFa | - | in-vitro, | PC, | AsPC-1 | - | in-vitro, | PC, | MIA PaCa-2 | - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | LNCaP | - | in-vivo, | NA, | NA |
| 1992- | Part, | Parthenolide induces ROS-dependent cell death in human gastric cancer cell |
| - | in-vitro, | BC, | MGC803 |
| 2362- | SK, | RIP1 and RIP3 contribute to shikonin-induced glycolysis suppression in glioma cells via increase of intracellular hydrogen peroxide |
| - | in-vitro, | GBM, | U87MG | - | in-vivo, | GBM, | NA | - | in-vitro, | GBM, | U251 |
| 2355- | SK, | Pharmacological properties and derivatives of shikonin-A review in recent years |
| - | Review, | Var, | NA |
| 2222- | SK, | The anti-tumor effect of shikonin on osteosarcoma by inducing RIP1 and RIP3 dependent necroptosis |
| - | in-vitro, | OS, | U2OS | - | in-vitro, | OS, | 143B | - | in-vivo, | NA, | NA |
| 1342- | SK, | RIP1 and RIP3 contribute to shikonin-induced DNA double-strand breaks in glioma cells via increase of intracellular reactive oxygen species |
| - | in-vitro, | GBM, | NA | - | in-vivo, | NA, | NA |
| 2188- | SK, | Molecular mechanism of shikonin inhibiting tumor growth and potential application in cancer treatment |
| - | Review, | Var, | NA |
| 2197- | SK, | Shikonin derivatives for cancer prevention and therapy |
| - | Review, | Var, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:1066 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid